In conclusion, we identified BASP1 as a poor prognostic biomarker for HNSCC, revealed its potentiality in predicting immunotherapy response, and offered a novel candidate for stratifying patients in immunotherapy of HNSCC. The gene discussed is BASP1; the disease is head and neck squamous cell carcinoma.